In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Dong Chen, M.D., Ph.D., chair of the Division of Hematopathology in the Department of Laboratory Medicine and Pathology at Mayo Clinic. They discuss rare and inherited platelet disorders and esoteric laboratory testing of hematologic disorders.

This page lists updates posted to Mayo Clinic Labs during the month of September.

Register now – Nov. 20, 2024 This webinar will inform attendees on regulatory compliance and recent policy changes at the federal and state level relevant to hospital laboratory outreach programs. The topics will include germane regulatory summaries and updates, billing and reimbursement, and government enforcement. The focus will be to provide actionable knowledge and recommendations of best practices to achieve, and be prepared to demonstrate, an effective compliance program. This will provide helpful guidance to even the most compliant-minded laboratory operators.

In this episode of Mayo Clinic Laboratories’ “Leveraging the Laboratory” podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, speaks with outreach solutions strategists Ellen Dijkman Dulkes and Brianne Newton about how to establish processes that allow outreach programs to efficiently recover from road bumps and minimize visible impact to the customer.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice[...]

Tropical Storm Helene is approaching the Florida Gulf Coast and is expected to become a hurricane. These weather conditions may impact areas in the United States, including Alabama, Florida, Georgia, and South Carolina. We continue to monitor and track the situation with our logistics partners to minimize challenges. Clients in the affected areas should expect to be contacted directly if any routes are modified or canceled.

Founded in 2017, Mayo Clinic's Advanced Diagnostics Laboratory is a visionary space. In 2021, the lab developed the Mayo Complete Solid Tumor Panel, a clinically validated assay that analyzes 515 genes using next-generation sequencing. This multiple test panel, the first of its kind at Mayo, aids in selecting targeted therapies, diagnosing tumor types, and predicting prognosis, significantly improving patient care.

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

When Samantha Duke discovered she had breast cancer, she didn’t have to look far for support. Her mother Jane walked a similar path 16 years earlier. Inspired both by her mom and the strong network of healthcare physicians and professionals on her team, Samantha remained positive throughout her treatment and is committed to advancing research on breast cancer.

Unexpected events in the laboratory are an inevitability of the profession. The difference in whether it is manageable or chaotic comes down to the steps taken beforehand. By proactively preparing, you can drastically reduce the number of unknown variables to continue laboratory and outreach operations under less-than-ideal circumstances.

In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., interviews Shannon Strader, a resident doctor in cellular therapy at Mayo Clinic in Rochester, MN, to discuss trailblazing new connections in medicine.

In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by special guest Donald Thomas, M.D., a rheumatologist and lupus researcher. They discuss how Mayo Clinic Laboratories’ suite of innovative lupus testing, offered in collaboration with Progentec Diagnostics, is enhancing the care and quality of life for patients affected by systemic lupus erythematosus (SLE).

Thanks to advocacy work by a group of medical experts, including some from Mayo Clinic, the U.S. Department of Health and Human Services now recommends all states screen for infantile Krabbe disease to help save newborn lives.

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Aiming to advance understanding of hard-to-predict gastroenteropancreatic neuroendocrine tumors (GEP-NETs), Thermo Fisher Scientific joined forces with Mayo Clinic and BioPharma Diagnostics to validate and gain U.S. regulatory clearance of a novel, automated assay aimed at detecting a biomarker associated with the progressive disease.